NEW YORK, Jan. 17, 2017 /PRNewswire/ -- Cota, the leading data and technology platform for value-based precision medicine, today announced that the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute (NCI) designated comprehensive cancer center, will be using the CNA Guided Care™ Platform to help improve clinical and cost outcomes for cancer patients.
Using Cota technology, Karmanos will be able to understand variances in patient care delivery, treatment, utilization, and outcomes, starting with lung cancer patients, at its treatment locations. Additionally, the analysis provided by Cota's technology will create a baseline of the institution's cost variances for testing, drugs, procedures, and hospitalization, which can be evaluated per individual physician and treatment location. Cota's platform is powered by the patented Cota Nodal Address™ (CNA) system, a digital classification methodology that stratifies patients based on all the personal and clinical factors that matter to the individual. Each patient with the same CNA can be considered medically identical, and thus should have similar treatments and outcomes.
"The clinical and cost analysis from Cota will help empower our physicians to provide the most optimal, personalized cancer care at all of our treatment locations," said Gerold Bepler, president and CEO, Karmanos Cancer institute.
"Using real world data drawn directly from existing Electronic Health Record systems, Cota's patented CNA Guided Care Platform helps institutions improve outcomes while reducing total cost of care," said Eric Schultz, CEO of Cota. "We are proud that the Karmanos Cancer Institute, a leading NCI-designated cancer center, has chosen to use the Cota platform to assist not only their research and quality efforts but also value-based approaches which are important in an increasingly cost-conscious environment."
Cota is a technology platform that enables providers, payers, and life science companies involved in diagnosing and treating complex diseases to optimize the care of individual patients and lower the overall cost of the patient population served. It is powered by the patented Cota Nodal Address™ (CNA) system, a unique digital classification methodology built by leading physicians and data scientists. The CNA is the first and only system that precisely categorizes patient factors, their diseases and intended therapies, enabling precision medicine at scale.
Cota's technology enriches raw medical records to create research-grade data, and joins it with a suite of analysis, visualization, and management tools. This enables providers, payers, and life sciences companies to analyze, report on, and research outcomes, costs, treatments, and quality at any granularity and stage of the patient journey. The result is a constantly improving system that merges technology and science to help improve the lives of patients everywhere.
Press: Matthew Levin
Phone: +1 (646) 543-2682
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/karmanos-cancer-institute-selects-cota-cna-guided-care-platform-to-provide-insight-on-patient-clinical-and-cost-outcomes-300391572.html